AstraZeneca PLC
AZN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.71 | 0.44 | 0.03 | -15.25 |
| FCF Yield | 3.58% | 3.12% | 3.45% | 2.28% |
| EV / EBITDA | 14.75 | 17.37 | 25.63 | 37.07 |
| Quality | ||||
| ROIC | 10.30% | 9.32% | 6.54% | -0.54% |
| Gross Margin | 81.12% | 81.95% | 72.06% | 66.76% |
| Cash Conversion Ratio | 1.36 | 1.50 | 3.92 | -22.50 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.83% | 6.98% | 18.55% | 15.34% |
| Free Cash Flow Growth | 10.78% | -9.26% | 92.32% | 71.59% |
| Safety | ||||
| Net Debt / EBITDA | 1.60 | 1.70 | 2.53 | 4.76 |
| Interest Coverage | 5.95 | 5.16 | 2.82 | 0.83 |
| Efficiency | ||||
| Inventory Turnover | 1.93 | 1.52 | 2.64 | 1.38 |
| Cash Conversion Cycle | 134.77 | 162.21 | 138.95 | 260.08 |